≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Other dermatomyositis

DOID EFO Endpoint Browser PheWeb

M13_DERMATOMYOTH

dermatomyositis: Dermatomyositis (DM) is a type of idiopathic inflammatory myopathy characterized by evocative skin lesions and symmetrical proximal muscle weakness.

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — M33.1
  • Hospital discharge: ICD-9 — 7103B
  • Hospital discharge: ICD-8 — 7160
  • Cause of death: ICD-10 — M33.1
  • Cause of death: ICD-9 — 7103B
  • Cause of death: ICD-8 — 7160

2 out of 7 registries used, show all original rules.

184

4. Check minimum number of events

None

184

5. Include endpoints

None

184

6. Filter based on genotype QC (FinnGen only)

177

Control definitions (FinnGen only)

Control exclude
M13_SYSTCONNECT

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
M33
Name in latin
Alia dermatomyositis

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 994 672 312
Only index persons 759 525 234
Unadjusted period prevalence (%)
Whole population 0.02 0.02 0.01
Only index persons 0.02 0.02 0.01
Median age at first event (years)
Whole population 54.13 53.64 54.89
Only index persons 51.33 51.38 51.23

-FinnGen-

Key figures

All Female Male
Number of individuals 177 125 52
Unadjusted period prevalence (%) 0.04 0.04 0.02
Median age at first event (years) 53.98 52.75 56.94

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
184
Matched controls
1840
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M33.1
ICD-10 Finland
Other dermatomyositis
+∞
235.8
172
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
25.5
115.4
113
108
P01BA02
ATC
hydroxychloroquine; oral
20.2
87.3
83
72
M33.9
ICD-10 Finland
Dermatopolymyositis, unspecified
+∞
86.4
76
*
L04AX01
ATC
azathioprine; systemic
31.8
79.7
56
25
L04AX03
ATC
methotrexate; systemic
16.5
79.5
88
97
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
11.8
53.7
68
87
M33.2
ICD-10 Finland
Polymyositis
+∞
42.3
39
*
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
7.1
36.6
131
473
H02AB06
ATC
prednisolone; systemic
8.8
35.4
152
643
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
10.8
34.6
42
49
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
8.5
31.9
48
73
M35.9
ICD-10 Finland
Systemic involvement of connective tissue, unspecified
314.4
27.5
27
*
H02AB07
ATC
prednisone; oral
6.2
27.0
58
127
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
9.3
26.9
36
47
M05BA04
ATC
alendronic acid; oral
6.9
26.4
48
89
NXL00
NOMESCO Finland
Biopsy of muscle
274.2
24.3
24
*
L04AA06
ATC
mycophenolic acid; systemic
42.6
23.8
29
8
ZX120
NOMESCO Finland
Intravenous
6.1
20.6
41
82
L04AD01
ATC
ciclosporin; systemic
28.7
18.8
25
10
L01BA01
ATC
methotrexate; systemic
14.1
17.1
29
24
M33.0
ICD-10 Finland
Juvenile dermatomyositis
+∞
16.9
16
*
M60.9
ICD-10 Finland
Myositis, unspecified
99.3
16.9
18
*
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.6
16.0
86
363
L30.9
ICD-10 Finland
Dermatitis, unspecified
3.7
15.5
66
239
71600
ICD-8 Finland
Polymyositis and dermatomyositis, Dermatomyositis
+∞
14.8
14
*
M33
ICD-10 Finland
Dermatopolymyositis
+∞
14.8
14
*
D07AC01
ATC
betamethasone; topical
3.3
14.0
94
447
7103B
ICD-9 Finland
Diffuse diseases of connective tissue, Dermatomyositis[DERMATOMYOSITIS ADULTORUM]
+∞
13.7
13
*
G72.9
ICD-10 Finland
Myopathy, unspecified
24.7
13.2
18
8
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.2
13.1
117
649
J84.9
ICD-10 Finland
Interstitial pulmonary disease, unspecified
26.6
12.7
17
7
J84.1
ICD-10 Finland
Other interstitial pulmonary diseases with fibrosis
17.5
12.4
19
12
NJ3CG
NOMESCO Finland
Extensive MRI examination of extremities with median high magnet
40.5
12.4
15
*
R4110
NOMESCO Finland
Physiotherapy
3.1
12.3
81
375
UGC12
NOMESCO Finland
Flexible bronchoscopy
5.1
11.9
27
60
L04AA01
ATC
[U] ciclosporin
24.8
11.8
16
7
D07AB08
ATC
desonide; topical
3.9
11.8
40
122
J99.1*M33.9
ICD-10 Finland
Respiratory disorders in dermatopolymyositis
+∞
11.6
11
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.9
11.5
39
119
L88
ICPC
Rheumatoid/seropositive arthritis
6.3
11.3
20
35
NJ3BG
NOMESCO Finland
MRI examination of extremities with high intensity magnet
46.3
11.1
13
*
M05BA07
ATC
risedronic acid; oral
8.6
10.8
23
30
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.4
10.6
46
165
D07AC13
ATC
mometasone; topical
2.9
10.5
72
335
M60.8
ICD-10 Finland
Other myositis
116.4
10.5
11
*
NGA20
NOMESCO Finland
Exploration of soft tissue knee or lower leg, open
116.4
10.5
11
*
J99.1*M33.2
ICD-10 Finland
Respiratory disorders in polymyositis
+∞
10.5
10
*
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
34.7
10.5
13
*
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
4.6
10.4
27
67
M05BX04
ATC
denosumab; parenteral
5.0
9.6
22
49
XX9XE
NOMESCO Finland
Other ultrasound examination
23.2
9.5
13
6
M35.1
ICD-10 Finland
Other overlap syndromes
+∞
9.5
9
*
1XC02, ,
NOMESCO Finland
+∞
9.5
9
*
XQ848
NOMESCO Finland
Dermatological photography
9.1
9.3
19
23
R4120
NOMESCO Finland
Occupational therapy
4.2
9.3
27
73
J84.8
ICD-10 Finland
Other specified interstitial pulmonary diseases
38.8
9.1
11
*
JN4BD
NOMESCO Finland
Extensive body CT
3.6
8.9
33
106
L93.0
ICD-10 Finland
Discoid lupus erythematosus
94.2
8.5
9
*
E0000UV, ,
ATC
2.5
8.5
97
569
QBA99
NOMESCO Finland
Other local destruction of skin of trunk
35.0
8.2
10
*
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.6
7.8
61
297
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
4.5
7.8
20
49
Z3226
NOMESCO Finland
Physiotherapist
2.7
7.7
52
235
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
9.5
7.7
15
17
M13.9
ICD-10 Finland
Arthritis, unspecified
3.9
7.6
24
69
HA1AA
NOMESCO Finland
X-ray mammography
3.4
7.6
29
95
M32.9
ICD-10 Finland
Systemic lupus erythematosus, unspecified
83.3
7.5
8
*
Z2221
NOMESCO Finland
Medical doctor
2.4
7.5
69
363
R4190
NOMESCO Finland
Nutritional therapy
6.8
7.5
18
29
D07AB02
ATC
hydrocortisone butyrate; topical
2.4
7.4
70
372
XPX04
NOMESCO Finland
Angioscopy
+∞
7.3
7
*
L99
ICPC
Musculoskeletal disease other
8.5
7.3
15
19
M81.4
ICD-10 Finland
Drug-induced osteoporosis
31.4
7.2
9
*
XG410
NOMESCO Finland
Flow-volume spirometry
7.5
7.2
16
23
XG470
NOMESCO Finland
Measurement of diffusion capastity of the lungs
10.7
7.2
13
13
TPH04
NOMESCO Finland
Cathetrisation of vein
2.6
7.1
52
245
TQW80
NOMESCO Finland
Local dermatologic skincare
8.8
7.0
14
17
PJ2AE
NOMESCO Finland
Lymphnode ultrasound examination
41.6
6.8
8
*
ZXE10
NOMESCO Finland
More than one and less than three hours
2.2
6.4
82
489
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
3.2
6.4
27
94
D02AE01
ATC
carbamide; topical
4.0
6.3
18
48
TGC00
NOMESCO Finland
Bronchial lavation
8.1
6.2
13
17
Z01.8
ICD-10 Finland
Other specified special examinations
2.4
6.2
51
252
C03CA01
ATC
furosemide; systemic
2.2
6.1
67
374
E000001, ,
ATC
2.4
6.1
48
232

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 500 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Proper column names.
  • Show details (e.g. Fisher or Chi-square test, N cases and N controls) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV not working.
  • No filters and sorters.
  • Limited amount of endpoints with TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP Concept
ln(OR) -5y
ln(OR) -1y
ln(OR) -1m
ln(OR) d0
ln(OR) +1m
ln(OR) +1y
ln(OR) +5y
MCC -5y
MCC -1y
MCC -1m
MCC d0
MCC +1m
MCC +1y
MCC +5y
Dermatopolymyositis, unspecified
M33.9 (45553169)
Polymyositis
M33.2 (45567548)
Systemic involvement of connective tissue, unspecified
M35.9 (45553174)
Jo-1 extractable nuclear Ab [Units/volume] in Serum by Immunoassay
35333-4 (3036086)
Other dermatomyositis
M33.1 (45538753)
SMOKING - SMOKE2: no - SMOKE3: never - SMOKE5: Unspecified
SMOKING-2-3-0 (2002330113)
Aldolase [Enzymatic activity/volume] in Serum or Plasma
1761-6 (3027953)
Dermatopolymyositis
M33 (45567546)
rituximab
L01FA01 (955167)
sulfamethoxazole and trimethoprim
J01EE01 (21602961)
IgG [Mass/volume] in Serum or Plasma
2465-3 (3005719)
Smith extractable nuclear Ab [Units/volume] in Serum
11090-8 (3016921)
DNA double strand Ab [Units/volume] in Serum
5130-0 (3023420)
Body height measure
50373000 (4177340)
Body mass index
60621009 (4245997)
Myosin Ab [Presence] in Serum or Plasma by Immunoblot
72458-3 (43055089)
Inpatient Visit
IP (9201)
Measurement of bone density from two or more locations with X-ray
NK6QA (2001308500)
Biopsy of skin and subcutaneous tissue
TQX10 (2001310152)
Physiotherapy
R4110 (2001310233)
prednisolone
A07EA01 (21600653)
prednisolone; oral, parenteral
H02AB06 (21602734)
Myoglobin [Mass/volume] in Serum or Plasma
2639-3 (3005895)
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 (3007220)
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 (3013707)
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 (3035995)
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X (38003841)
Neurology
13 (38004458)
Pulmonary Disease
29 (38004472)
Rheumatology
66 (38004491)
Dermatitis, unspecified
L30.9 (45572271)
methotrexate
L01BA01 (21601423)
methotrexate; oral, parenteral
L04AX03 (21603929)
calcium (different salts in combination); oral
A12AA20 (21600872)
Outpatient Visit
OP (9202)
hydroxychloroquine; oral
P01BA02 (21604889)
Monocytes [#/volume] in Blood
26484-6 (3001604)
Eosinophils [#/volume] in Blood
26449-9 (3013115)
Basophils [#/volume] in Blood
26444-0 (3006315)
Lymphocytes [#/volume] in Blood
26474-7 (3019198)
Monocytes/Leukocytes in Blood
26485-3 (3019069)
Lymphocytes/Leukocytes in Blood
26478-8 (3002030)
Basophils/Leukocytes in Blood
30180-4 (3022096)
Eosinophils/Leukocytes in Blood
26450-7 (3006504)
Neutrophils/Leukocytes in Blood
26511-6 (3018010)
betamethasone
A07EA04 (21600656)
betamethasone
C05AA05 (21601610)
betamethasone
D07AC01 (21602120)
betamethasone
S02BA07 (21605169)
Differential panel, method unspecified - Blood
69738-3 (42870588)
Office Visit
OMOP4822458 (581477)
prednisone
A07EA03 (21600655)
prednisone; oral
H02AB07 (21602735)
Neutrophils [#/volume] in Blood by Automated count
751-8 (3013650)
Internal Medicine
11 (38004456)
Inpatient Hospital
21 (8717)
Outpatient Hospital
22 (8756)
pantoprazole; oral, parenteral
A02BC02 (21600097)
Pharmacy visit
OMOP4822462 (581458)
Nuclear Ab [Titer] in Serum
29953-7 (3037522)
Urinalysis macro (dipstick) panel - Urine
24357-6 (3037467)
Normoblasts [#/volume] in Blood
715-3 (3021589)
hydrocortisone
D07AA02 (21602102)
hydrocortisone butyrate
D07AB02 (21602106)
hydrocortisone buteprate
D07AB11 (21602115)
hydrocortisone aceponate
D07AC16 (21602135)
hydrocortisone
A07EA02 (21600654)
hydrocortisone
C05AA01 (21601608)
alendronic acid; oral
M05BA04 (21604152)
hydrocortisone
S02BA01 (21605166)
MCV [Entitic mean volume] in Red Blood Cells
30428-7 (3024731)
Hemoglobin [Mass/volume] in Blood
718-7 (3000963)
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 (3009542)
Platelets [#/volume] in Blood
26515-7 (3007461)
Leukocytes [#/volume] in Blood
26464-8 (3010813)
Erythrocytes [#/volume] in Blood
26453-1 (3026361)
MCH [Entitic mass]
28539-5 (3035941)
esomeprazole; oral, parenteral
A02BC05 (21600100)
Thorax X-ray examination
GD1AA (2001303617)
Laboratory Visit
OMOP4822461 (32036)
Case Management Agency
251B00000X (38004193)
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 (3020460)
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 (3006923)
mometasone
D07AC13 (21602132)
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 (3002385)
combinations of corticosteroids
D07AB30 (21602118)
combinations of corticosteroids
D07XB30 (21602188)
Connective tissue diseases, rheumatoid arthritis and comparable disease
202 (2001600200)
Physical Medicine And Rehabilitation
25 (38004468)
Creatinine [Moles/volume] in Serum or Plasma
14682-9 (3020564)
Supplier / Service Provider
OMOP5117446 (33004)
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 (3003338)
General Surgery
2 (38004447)
Joint ultrasound examination not elsewhere classified
NK4XE (2001308469)

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
54
61
12.11
46.14
2.1
1.4
2.49
3.22
iu/ml
0.22
14
11
46
46
13.00
42.50
1.6
1.1
0.20
0.25
g/l
2.85
46
46
46
48
12.44
41.26
1.6
1.1
1.13
1.25
g/l
1.28
46
48
87
216
6.74
36.65
2.0
1.3
663.81
453.33
titre
0.78
42
45
146
797
5.03
19.71
19.7
5.8
0.57
0.57
e9/l
0.05
141
689
148
822
5.09
19.37
20.1
6.2
0.17
0.18
e9/l
0.60
143
721
146
803
4.96
19.35
19.9
5.8
0.04
0.04
e9/l
0.26
141
692
110
512
3.86
18.15
18.4
5.2
—
—
—
0
0
149
891
4.53
16.15
22.5
10.3
4.07
4.11
e9/l
0.08
143
778
20
11
20.20
13.71
1.3
1.0
—
—
—
0
0
19
9
23.35
13.65
1.2
1.0
—
—
—
0
0
20
12
18.51
13.32
1.3
1.0
—
—
—
0
0
98
497
3.08
12.76
5.2
4.0
7.39
7.40
ph
1.11
81
343
29
67
4.95
12.20
1.2
1.2
—
—
—
0
0
49
188
3.19
10.04
1.4
1.6
—
—
—
0
0
91
501
2.62
9.34
12.2
6.3
—
—
—
0
0
37
126
3.42
9.14
1.3
1.5
—
—
—
0
0
38
135
3.29
8.76
8.1
4.9
0.83
0.72
%
0.18
18
48
123
799
2.63
8.72
10.7
7.1
1.21
1.21
mmol/l
0.19
113
683
55
252
2.69
8.00
1.6
1.6
—
—
—
0
0
35
126
3.20
7.86
6.9
5.1
1.00
0.64
%
0.37
15
42
19
45
4.59
7.68
2.8
3.0
4.43
1.57
index
—
7
28
82
462
2.40
7.64
4.6
3.0
0.17
0.52
e6/l
1.97
62
329
107
680
2.37
7.53
4.9
3.4
6.36
6.25
ph
0.40
53
367
33
118
3.19
7.48
1.3
3.4
63.92
66.33
g/l
0.91
33
110
34
124
3.14
7.46
8.7
5.2
0.14
0.16
%
0.06
14
37
35
132
3.04
7.25
8.5
5.5
0.00
0.10
%
0.49
13
39
68
363
2.39
7.05
2.2
1.5
2.17
2.48
g/l
0.64
52
211
74
410
2.35
7.05
5.0
4.1
—
—
—
0
0
111
731
2.31
7.00
23.9
11.2
0.00
0.00
e9/l
0.07
101
592
97
612
2.24
6.69
6.4
3.8
42.01
118.82
e6/l
0.86
68
416
122
857
2.26
6.31
6.3
3.8
0.00
0.00
estimate
-0.00
23
197
124
877
2.27
6.30
6.3
3.8
0.00
0.00
estimate
-0.00
22
191
87
538
2.17
6.17
4.7
3.1
168.19
175.17
e6/l
0.01
67
403
122
863
2.23
6.11
6.3
3.8
0.00
8.00
estimate
0.50
23
203
25
86
3.21
6.00
8.2
4.0
—
—
—
0
0
77
468
2.11
5.58
4.4
2.9
—
0.00
—
0
11
12
17
7.47
5.53
2.1
1.2
—
—
—
0
0
12
17
7.47
5.53
2.1
1.2
—
—
—
0
0
12
17
7.47
5.53
2.1
1.2
—
—
—
0
0
12
17
7.47
5.53
2.1
1.2
—
—
—
0
0
13
21
6.57
5.49
5.1
2.0
4.29
5.96
e9/l
1.12
13
21
22
75
3.20
5.35
1.7
2.3
—
—
—
0
0
42
202
2.40
5.35
2.1
1.4
—
—
—
0
0
38
176
2.46
5.24
10.7
8.0
11.12
12.47
kpa
0.90
32
170
38
176
2.46
5.24
10.7
8.0
5.49
5.05
kpa
1.40
32
170
66
389
2.09
5.11
5.8
3.8
—
0.38
—
0
8
37
173
2.43
4.99
10.8
8.2
7.42
7.42
ph
0.14
19
99
16
38
4.51
4.96
5.0
2.0
64.00
61.81
%
0.23
16
38
37
176
2.38
4.80
2.3
1.7
—
—
—
0
0
36
170
2.39
4.75
11.1
8.3
2.72
0.75
mmol/l
1.15
29
139
62
368
2.03
4.64
10.3
4.8
—
—
—
0
0
30
132
2.52
4.59
1.3
1.2
—
—
—
0
0
39
195
2.27
4.51
3.9
3.0
3.56
5.61
e9/l
1.04
39
178
21
81
2.80
4.14
2.0
2.3
0.00
0.03
estimate
0.49
13
32
46
254
2.08
4.14
4.2
3.0
3.45
2.75
e6/l
0.21
26
121
50
286
2.03
4.09
1.9
1.9
—
—
—
0
0
52
307
1.97
3.87
4.5
4.0
205.80
258.77
ng/l
0.16
46
238
11
24
4.80
3.81
1.2
1.4
121.76
160.33
au/ml
—
5
6
8
12
6.91
3.71
2.5
1.8
49.24
38.44
%
—
8
12
52
320
1.87
3.38
3.5
2.7
527.81
520.32
mosm/kgh2o
0.09
47
277
6
7
8.81
3.28
1.0
1.1
94.50
87.99
iu/ml
—
6
7
29
146
2.17
3.27
1.2
1.4
—
—
—
0
0
73
503
1.75
3.25
3.1
3.0
—
—
—
0
0
64
426
1.77
3.21
1.5
1.2
1.10
2.01
u/ml
0.68
14
122
13
44
3.10
3.20
1.2
1.4
—
74.00
—
0
5
9
22
4.24
2.92
1.7
2.4
—
—
—
0
0
9
22
4.24
2.92
1.9
1.8
—
—
—
0
0
29
153
2.06
2.91
2.1
2.2
0.00
0.08
estimate
0.49
12
39
27
141
2.07
2.78
10.0
8.8
—
—
—
0
0
32
179
1.95
2.74
3.3
4.7
2.78
71.25
ug/l
0.89
25
147
8
19
4.35
2.71
1.5
1.3
—
—
—
0
0
28
151
2.01
2.65
3.0
1.4
—
—
—
0
0
10
31
3.35
2.56
1.1
1.1
2.20
5.00
u/ml
—
5
13
43
635
0.58
2.53
2.9
3.1
—
—
—
0
0
9
26
3.58
2.52
1.7
1.5
—
—
—
0
0
7
16
4.50
2.50
1.0
1.3
—
—
—
0
0
9
27
3.45
2.42
1.1
1.1
—
—
—
0
0
36
218
1.81
2.42
1.1
1.2
—
—
—
0
0
7
20
3.60
2.07
1.0
1.0
—
—
—
0
0
134
1494
0.62
2.07
4.8
5.0
5.57
5.93
mmol/l
4.17
129
1370
37
238
1.69
2.02
3.6
2.0
—
—
—
0
0
40
265
1.65
1.96
1.8
1.6
961.85
1267.90
nmol/l
1.70
34
200
64
475
1.53
1.95
5.1
3.2
0.00
0.00
estimate
-0.00
21
149
15
72
2.18
1.92
11.3
4.2
36.96
36.93
°c
0.31
15
72
12
52
2.40
1.92
1.1
1.3
—
—
—
0
0
5
12
4.25
1.83
1.0
1.3
—
—
—
0
0
82
650
1.47
1.79
6.0
3.7
0.00
0.04
estimate
1.15
20
161
6
18
3.41
1.76
1.0
1.0
—
—
—
0
0
143
1557
0.63
1.70
5.6
5.9
2.84
2.73
mmol/l
0.86
137
1437
36
241
1.61
1.69
2.4
1.9
32.79
29.29
s
0.85
36
235
90
733
1.45
1.68
15.8
12.1
1.34
1.21
inr
1.03
74
593
5
14
3.64
1.62
1.0
1.1
—
—
—
0
0
34
227
1.61
1.62
12.9
7.0
103.97
104.36
mmol/l
0.19
34
227
7
26
2.76
1.59
1.7
2.2
2.64
147.65
u/ml
—
7
26
55
412
1.48
1.57
4.2
2.8
324.75
337.55
umol/l
0.43
48
357
133
1460
0.68
1.49
4.4
4.3
1.28
1.27
mmol/l
0.07
128
1330
44
318
1.50
1.49
1.3
1.3
35.64
34.79
iu/ml
0.02
11
105
142
1538
0.66
1.45
5.2
5.1
4.76
4.69
mmol/l
0.36
136
1419
21
128
1.72
1.40
1.8
2.2
0.12
1.14
e6/l
0.76
21
122
26
170
1.62
1.35
3.1
3.2
7.37
7.39
ph
0.82
15
90
20
122
1.72
1.34
3.0
3.3
52.07
82.18
ng/l
2.45
20
106
142
1531
0.68
1.30
5.2
5.0
1.49
1.52
mmol/l
0.39
135
1407
9
44
2.10
1.29
6.3
2.8
7.40
7.42
ph
—
9
44
30
207
1.54
1.25
1.4
1.3
—
—
—
0
0
49
377
1.41
1.20
1.7
1.8
1.13
1.28
mg/l
0.21
38
300
5
20
2.54
1.16
3.0
4.0
—
—
—
0
0
7
30
2.38
1.13
3.9
3.6
0.69
0.81
nmol/l
—
7
25
39
291
1.43
1.12
1.3
1.3
10.52
18.27
u/ml
0.48
12
102
7
31
2.31
1.11
1.1
2.1
—
—
—
0
0
5
21
2.42
1.10
1.0
12.5
—
—
—
0
0
16
100
1.66
1.00
2.8
3.3
24.99
24.48
mmol/l
0.42
16
100
60
493
1.32
0.96
7.1
3.9
0.00
0.01
estimate
0.50
22
183
9
51
1.80
0.96
4.2
1.8
27.56
24.88
mmol/l
—
9
51
20
136
1.53
0.91
1.6
1.7
—
—
—
0
0
19
129
1.53
0.87
1.5
3.5
84.57
73.47
e9/l
0.36
13
99
63
528
1.29
0.87
2.5
2.4
—
—
—
0
0
8
45
1.81
0.85
1.1
1.2
—
—
—
0
0
0
24
0.00
0.80
0.0
2.2
—
31.96
—
0
24
0
24
0.00
0.80
0.0
1.3
—
274.65
—
0
17
86
758
1.25
0.77
3.7
2.7
—
—
estimate
—
0
0
7
39
1.83
0.73
5.1
2.9
54.43
38.24
u/ml
—
7
39
47
389
1.28
0.71
6.5
3.8
1.02
1.02
kg/l
0.19
37
250
5
28
1.81
0.66
2.8
2.1
—
—
—
0
0
5
29
1.74
0.64
4.8
1.8
83.22
90.17
%
—
5
29
5
30
1.68
0.62
4.6
2.1
—
—
—
0
0
0
20
0.00
0.60
0.0
1.1
—
3.95
—
0
9
15
108
1.42
0.55
16.7
7.6
27.35
24.95
mmol/l
1.11
15
108
140
1466
0.81
0.53
6.6
6.3
39.66
39.14
mmol/mol
0.29
135
1367
161
1552
1.30
0.51
34.0
15.1
21.08
23.01
mg/l
0.34
147
1262
13
96
1.38
0.43
2.8
2.6
0.63
0.63
%
0.02
13
96
13
96
1.38
0.43
2.8
2.7
1.18
1.23
%
0.09
13
96
5
33
1.53
0.41
1.2
1.1
—
—
—
0
0
5
33
1.53
0.41
8.8
3.1
3.66
2.96
mmol/l
—
5
21
5
33
1.53
0.41
8.8
3.1
5.42
5.07
kpa
—
5
33
5
33
1.53
0.41
8.8
3.1
7.74
8.74
kpa
—
5
33
5
33
1.53
0.41
3.0
2.4
6.00
92.58
ug/min
—
5
16
0
15
0.00
0.41
0.0
19.8
—
1007.13
—
0
15
0
17
0.00
0.41
0.0
5.2
—
8.54
—
0
17
14
106
1.35
0.40
1.1
1.3
—
—
—
0
0
0
19
0.00
0.39
0.0
1.1
—
0.85
—
0
8
156
1602
0.83
0.35
23.9
13.6
—
—
—
0
0
6
47
1.29
0.32
3.8
2.3
1.11
1.37
mg/l
—
6
41
7
52
1.36
0.31
1.3
1.1
—
—
—
0
0
75
698
1.13
0.30
2.6
2.0
92.95
97.92
pmol/l
0.55
43
349
55
502
1.14
0.30
3.5
3.3
23.28
49.18
mg/l
1.35
38
316
5
71
0.70
0.26
1.4
1.0
—
—
—
0
0
9
73
1.24
0.26
1.0
1.1
—
—
—
0
0
5
37
1.36
0.23
5.0
1.7
7.90
8.05
kpa
—
5
37
5
42
1.20
0.21
1.8
2.6
52.52
57.09
%
—
5
42
0
11
0.00
0.21
0.0
1.5
—
9.23
—
0
11
0
10
0.00
0.21
0.0
1.3
—
0.45
—
0
5
0
13
0.00
0.21
0.0
1.5
—
13.31
—
0
13
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
14
0.00
0.20
0.0
1.0
—
318.25
—
0
8
0
14
0.00
0.20
0.0
1.4
—
0.71
—
0
14
0
14
0.00
0.20
0.0
3.9
—
—
—
0
0
51
476
1.10
0.19
2.1
1.7
20.39
21.13
nmol/l
0.12
45
398
69
656
1.08
0.17
2.5
2.1
—
—
—
0
0
49
460
1.09
0.16
1.4
1.4
—
—
—
0
0
6
80
0.74
0.16
3.2
1.8
—
—
—
0
0
58
550
1.08
0.15
3.3
3.1
6.01
7.28
mmol/l
2.06
50
465
17
191
0.88
0.14
2.4
3.0
1.70
0.82
ug/l
0.37
11
125
5
47
1.07
0.09
1.2
2.8
56.30
58.56
%
—
5
47
64
619
1.05
0.09
3.8
3.7
99.91
34.02
ng/l
0.79
54
416
144
1458
0.94
0.08
6.8
5.6
1.73
1.92
mu/l
1.26
137
1347
5
64
0.78
0.08
2.6
3.5
—
—
—
0
0
8
78
1.03
0.07
1.1
1.4
—
0.31
—
0
29
16
172
0.92
0.06
1.9
1.5
—
—
—
0
0
13
121
1.08
0.04
1.4
1.2
45.39
126.24
u/ml
—
7
48
23
221
1.05
0.03
1.3
1.2
—
—
—
0
0
31
318
0.97
0.02
3.8
5.6
2.34
1.97
ug/l
0.20
25
284
14
136
1.03
0.00
5.8
3.3
—
—
—
0
0
124
1244
0.99
0.00
5.8
4.6
14.79
14.76
pmol/l
0.05
118
1138
69
694
0.99
0.00
2.0
1.9
1.29
1.36
mmol/l
0.37
60
582
51
513
0.99
0.00
3.5
4.0
4.20
8.93
mg/mmol
1.20
29
305
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
5
49
1.02
-0.00
7.8
7.5
—
—
—
0
0
9
93
0.97
-0.00
1.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.2
—
2180.00
—
0
5
0
5
0.00
-0.00
0.0
2.6
—
1.16
—
0
5
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
8.30
—
0
5

Mortality – FinRegistry

↥

Association

Association between endpoint M13_DERMATOMYOTH and mortality.

Females

Parameter HR [95% CI] p-value
M13_DERMATOMYOTH 2.82 [2.11, 3.76] < 0.001
Birth year 1.001 [0.99, 1.01] 0.762

During the follow-up period (1.1.1998 — 31.12.2019), 120 out of 411 females with M13_DERMATOMYOTH died.

Males

Parameter HR [95% CI] p-value
M13_DERMATOMYOTH 3.103 [2.28, 4.22] < 0.001
Birth year 0.985 [0.98, 0.99] 0.002

During the follow-up period (1.1.1998 — 31.12.2019), 69 out of 201 males with M13_DERMATOMYOTH died.

Mortality risk

Mortality risk for people of age

years, who have M13_DERMATOMYOTH.

N-year risk Females Males
1 0.228% 0.515%
5 1.755% 3.094%
10 4.592% 7.916%
15 9.262% 14.67%
20 16.456% 24.478%

Relationships between endpoints

↥

Index endpoint: M13_DERMATOMYOTH – Other dermatomyositis

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data